I think the question is, with all this lateral growth like pharmajanes and Sovereign (which works with 300 collectives) and SK buying a collective and contract servicing 15 others and some very exciting stuff going on in Berkeley Bio and their cancer research and with their proprietary licensed machines for purifying and separating CBD,  and some serious cash that can flow from phamajanes, and 18mil AR with $800k in cash from patient medicine and other revenue, is this company worth a whole lot more than only .011? Say you got under 600m shares.